University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

12-2008

Synthesis and Evaluation of Tetramic Acids as Antimicrobial
Agents
Jason B. Wilson
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Pharmaceutics and Drug
Design Commons

Recommended Citation
Wilson, Jason B. , "Synthesis and Evaluation of Tetramic Acids as Antimicrobial Agents" (2008). Theses
and Dissertations (ETD). Paper 367. http://dx.doi.org/10.21007/etd.cghs.2008.0354.

This Thesis is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.

Synthesis and Evaluation of Tetramic Acids as Antimicrobial Agents
Abstract
As bacterial infectious diseases are a major cause of morbity and mortality throughout the world, and
many causative organisms are resistant to currently available antibiotics, the motivation for the
development of new drugs is readily apparent. A number of natural products exhibiting antimicrobial
activity possess a tetramic acid (2,4-pyrrolidinedione) functional group. As their antibacterial mechanism
of action is different from that of many of the currently available antibiotics, these compounds have
potential to serve as a basis for a pharmacophore in synthetic compounds. However, toxicity to
eukaryotic cells is frequently a problem with currently known tetramic acids. The purpose of the project,
as outlined in the following pages, is to demonstrate a method of synthesis of a small library of
compounds containing the tetramic acid ring, and to illustrate their structure-activity relationship as
agents both having activity against Gram-positive bacteria and possessing low hemolytic activity. Chapter
One takes an overview of a number of the different classes of antibiotics available today, with emphasis
on their method of action, then covers several naturally occurring tetramic acid compounds with antibiotic
activity, and finally methods of synthesis. Chapter Two details the methods used to synthesize and
characterize the set of compounds and examines their activity against a set of Gram-positive bacteria,
with the purpose of clarifying their structure-activity relationship.
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Abstract
As bacterial infectious diseases are a major cause of morbity and mortality throughout
the world, and many causative organisms are resistant to currently available antibiotics,
the motivation for the development of new drugs is readily apparent. A number of
natural products exhibiting antimicrobial activity possess a tetramic acid (2,4pyrrolidinedione) functional group. As their antibacterial mechanism of action is
different from that of many of the currently available antibiotics, these compounds have
potential to serve as a basis for a pharmacophore in synthetic compounds. However,
toxicity to eukaryotic cells is frequently a problem with currently known tetramic acids.
The purpose of the project, as outlined in the following pages, is to demonstrate a method
of synthesis of a small library of compounds containing the tetramic acid ring, and to
illustrate their structure-activity relationship as agents both having activity against Grampositive bacteria and possessing low hemolytic activity. Chapter One takes an overview
of a number of the different classes of antibiotics available today, with emphasis on their
method of action, then covers several naturally occurring tetramic acid compounds with
antibiotic activity, and finally methods of synthesis. Chapter Two details the methods
used to synthesize and characterize the set of compounds and examines their activity
against a set of Gram-positive bacteria, with the purpose of clarifying their structureactivity relationship.
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Chapter 1. Introduction
There is an urgent need for antibacterial agents with distinct modes of action due to
increased prevalence of bacteria resistant to current clinically used antibiotics. The need
for novel antibiotics is well demonstrated by the emergence of strains of multiple-drug
resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). S. aureus
is a frequent cause of life-threatening diseases, such as pneumonia, endocarditis, and a
condition known as necrotizing fasciitis, an infection of the fascia that can spread quickly
throughout the body and frequently necessitate amputations of affected limbs. These
bacteria are also the most common cause of infections of the skin, such as scalded skin
syndrome and impetigo, which can worsen and lead to infections of deeper tissue, such as
cellulitis or erysipelas. These bacteria are normally commensal residents of skin, but can
cause infection upon entering breaks (typically open wounds, although hair follicles can
sometimes be a route of entry.) In addition, these bacteria are sometimes a cause of
infectious keratitis (inflammation of the cornea), which can lead to scarring and loss of
eyesight. In the clinic, topical antibiotics, when used as prophylactics, can prevent
serious S. aureus infection in high-risk post-surgical patients, and are useful as treatments
for some types of skin infections such as impetigo.
Since its emergence in the 1960s, MRSA has primarily been a major cause of hospitalacquired infection. In recent decades, however, community-acquired MRSA (CAMRSA) strains have emerged and are now a significant cause of skin and soft tissue
infections in several community settings across the United States. These strains are
different from hospital-acquired strains, which tend to be less virulent, and they are
increasingly prevalent in both community and hospital settings. In view of the etiology
of disease by CA-MRSA and the growing concern stemming in both community and
hospital settings, the need for strategies to counteract this organism is even more
pressing.
Recently, the synthesis of a series of novel tetramic acid (2,4-pyrrolidinedione)
compounds that possess effective antibacterial activity has been reported.1, 2 Although
these agents are effective in vitro, they exhibit toxicity to mammalian cells, with a
pronounced tendency toward lysis of red blood cells.1, 2 This attribute would be expected
to cause undesirable or harmful side effects, ranging from skin irritation to systemic
toxicity, if the tetramic acids were used clinically. These agents possess lipophilic
functional groups, which are thought to be the root of the hemolytic activity due to
eukaryotic cell membrane penetration and disruption. The consequent focus of this
synthetic project is to improve the safety profile of this class of drugs by introducing
functional groups with reduced lipophilicity, with the aim of minimizing their hemolytic
activity but retaining their antimicrobial activity. Furthermore, a reduction in the
cytotoxicity of tetramic acids could lead to novel molecules with greater potential for
systemic administration. This chapter will begin by examining the properties and
mechanisms of action of current clinical antibiotics used to treat skin and skin structure
infections, then cover the mode of action of known tetramic acid antibiotics and, finally,
methods for their synthesis.

1

Current Antibiotics Used to Treat Skin and Soft Tissue Infections
As shown in Table 1.1, a number of antibiotics are currently used for the treatment of
skin and soft tissue infections; their methods of action (MOAs), however, are different
from those of tetramic acids. This section will cover a sample of the variety of
compounds currently in clinical use for such infections.
Inhibitors of Bacterial Cell Wall Synthesis
Penicillins
The development of β-lactam antibiotics was initiated in 1928 when Fleming noted the
antimicrobial properties of the a substance produced by spores of Penicillium
chrysogenum mold contaminating a culture of Staphylococcus aureus.3 Isolation of the
active component, Penicillin F (Figure 1.1), was accomplished in the 1940 by Florey,
Chain, and Heatley, and its clinical efficacy demonstrated shortly thereafter. Penicillin F
did not experience widespread clinical use, but a number of variations on it were soon
isolated, and some of these alternative penicillins are still in use today, most notably
benzylpenicillin, also termed penicillin G (Figure 1.1). Subsequent work on this
molecule permitted numerous semi-synthetic analogues with improved antimicrobial
spectrum and durability against bacterial defenses to be produced. The activity of the βlactam antibiotics lies in prevention of bacterial cell wall biosynthesis. The cell wall of
both Gram-positive and Gram-negative bacteria contains a cross-linked peptidoglycan
layer that provides support against lysis of the cells’ contents via osmosis. The
peptidoglycan layer consists of chains of alternating glucose and N- acetylmuramic acid
connected by O-glycosidic bonds. These chains are cross-linked via amino acids
connected to the muramic acid subunits to provide greater strength; typically, in S.
aureus, five amino acids are connected to the muramic acid, and to these amino acids are
Table 1.1. Methods of Action of Existing Topical Antibiotics.
Drug Type
Penicillins
Cephalosporins
Bacitracin
Mupirocin
Fusidic acid
Tetracyclines
Silver sulfadiazine
Daptomycin

Point and Method of Action
Cell wall assembly (inhibition of peptidoglycan cross-linking)
Cell wall assembly (inhibition of peptidoglycan cross-linking)
Cell wall assembly (inhibition of dephosphorylation)
Protein synthesis (inhibition of isoleucyl t-RNA
aminoacylation)
Protein synthesis (inhibition of elongation factor G)
Protein synthesis (inhibition of tRNA binding to ribosomal site)
DNA synthesis (inhibition of folate biosynthesis)
Cell membrane permeabilization (induction of K+ ion efflux)

Source: Modified with permission from Gelmetti, C. Local antibiotics in dermatology.
Dermatologic Therapy, 2008, 21, 187-195.4
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Figure 1.1. Earliest Penicillins.
attached a pentaglycine chain that connects the amino acids between peptidoglycan
chains. In the cross-linking, or transpeptidation step, a preassembled, peptidoglycan
chain (losing an alanine in the process) is attacked by a terminal glycine to connect the
chains. This process is catalyzed by the enzyme transpeptidase. The β-lactams prevent
cell wall cross-linking by mimicking the D-Ala-D-Ala substituent present in the crosslinking step; consequently, the β-lactam is attacked by a penicillin-binding-protein’s SerOH, leading to an irreversible attachment of the penicillin molecule to the protein. With
the penicillin-binding proteins rendered inactive, peptidoglycan cross-linking cannot
occur, and so bacterial cell walls weaken, leading to eventual lysis and cell death.
The earliest penicillins’ C7-N1 amide bond was highly acid labile, necessitating
parenteral administration to avoid the strongly acidic environment of the stomach;
however, α-amino substitution to the amide with electron-withdrawing groups, as in
ampicillin (Figure 1.2) helped to overcome this limitation. A major impediment to the
efficacy of the first β-lactams was the bacterial development of β-lactamases, enzymes
that hydrolyze the amide bond of the lactam ring, rendering it ineffective. Semi-synthetic
analogues of penicillin with resistance to lactamase-induced cleavage have been
developed; a key component of the structure-activity relationship (SAR) of these resistant
penicillins is the substitution of bulky groups at the α-amino position (as in methicillin,
Figure 1.2) to inhibit the action of β-lactamases without significantly reducing affinity for
penicillin-binding proteins.
Cephalosporins
Cephalosporins (Figure 1.3) are structurally and functionally highly similar to penicillins,
the main difference being an eight-membered rather than seven-membered bicyclic main
ring, which confers greater stability and consequent lower reactivity. This reduced
reactivity is typically compensated for by the presence of a leaving group (R) at the ring
carbon β to the carboxyl (COOR) group. Many cephalosporins have been generated
because of their inherent resistance to β-lactamases and increased spectrum of activity.
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Peptide-Based Cell Wall Inhibitors
An inhibitor of cell wall biosynthesis commonly in use as an antibacterial ointment is
bacitracin, a mixture of cyclic peptides synthesized by strains of Bacillus licheniformis.5,6
The main component of the mixture is a cyclic oligopeptide designated Bacitracin A
(Figure 1.4). Bacitracin functions by inhibiting the dephosphorylation of the C55isoprenyl pyrophosphate, which, in its dephosphorylated state, carries assembled
peptidoglycan units (with their attached amino acids) to an endogenous acceptor outside
the cell membrane.5,6 With the dephosphorylation step inhibited, the cell wall cannot be
assembled. Bacitracin is systemically toxic in humans, however, and thus is limited to
topical application.
Protein Biosynthesis Inhibitors
Several classes of topical antibiotics prevent the synthesis of proteins via action on
ribosomal components. These include mupirocin, fusidic acid, and tetracyclines.
Mupirocin
Mupirocin (Figure 1.5), a mixture of bacterially synthesized fatty acids, is employed in
the treatment of skin infections caused by S. aureus. Mupirocin is used solely as a topical
antibiotic since it undergoes in vivo hydrolysis, which prevents it from being effective
systemically. It functions by inhibiting bacterial isoleucyl t-RNA synthetase. When this
enzyme is blocked, isoleucine cannot be connected to a molecule of t-RNA. At low
concentrations, mupirocin is bacteriostatic, as its starvation of the cellular supply of
isoleucine arrests protein synthesis and triggers repression of RNA synthesis.7 At higher
concentrations, the mixture is bactericidal due to its blockade of protein synthesis and
multiple other effects on the cell, including cell wall damage.
Fusidic Acid
A compound isolated from the fungus Fusidium coccineum,4 fusidic acid (Figure 1.6)
inhibits protein biosynthesis by forming a complex with elongation factor G (EF-G) that
prevents it from dissociating from the ribosome.8 EF-G catalyzes the transfer of tRNA
from the ribosomal A site (to which an aminoacylated tRNA binds during protein
synthesis) to the P site (where the growing peptide chain is located prior to linkage with
the A site amino acid), but must dissociate from the ribosome to leave space for the next
aminoacylated tRNA to enter the A site. Halting this cycle does not kill bacteria, but
does halt their reproduction; fusidic acid’s action is specific to prokaryotic ribosomes. Its
main disadvantage is rapid emergence of resistance compared with other types of
antibiotics; it is also effective solely against Gram-positive bacteria.
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Tetracyclines
Tetracyclines (Figure 1.7) are a semi-synthetic class of drugs often prescribed as a
treatment for acne vulgaris. Their mode of action is binding to the bacterial 30S
ribosomal subunit and inhibition of aminoacyl-tRNA binding to the A site. Tetracyclines
are clinically bacteriostatic, in part because their interaction with the ribosome is
reversible.9 Microbial resistance to the tetracycline class, which occurs via efflux pumps,
ribosomal protection proteins (which interact with the ribosome and render it immune to
tetracycline-induced inactivation), and enzymatic inactivation of the drug, is now
widespread.9 This situation has significantly reduced their clinical utility.
DNA Biosynthesis Inhibitors
The first class of antimicrobials was a variety of fully synthetic drugs known as the
sulfonamides. This class of drugs acts by halting the biosynthesis of tetrahydrofolate, an
essential factor in the synthesis of the DNA bases guanine and adenine. Specifically,
they compete with the natural substrate (para-aminobenzoic acid) for the active site of
dihydropteroate synthase. Sulfonamides act selectively because bacteria synthesize
tetrahydrofolate de novo, whereas humans synthesize it from dietary folic acid. This
inhibition of DNA synthesis does not destroy bacteria, but prevents reproduction,
allowing the host’s immune system to eliminate the infection. As such, sulfonamides are
classified as bacteriostatic (i.e. inhibitors of bacterial reproduction) rather than
bactericidal. The most relevant preparation, commonly used to treat burns, is silver
sulfadiazine salt (Figure 1.8).
Membrane-Destabilizing Agents
Daptomycin (Figure 1.9), a cyclic lipopeptide derived from Streptomyces roseosporus,
possesses an unusual antibacterial mode of action in that it depolarizes bacterial
membranes by causing the Ca2+-dependent gradual release of K+ ions, but without
forming pores.10 This activity severely and quickly reduces the viability of a bacterial
culture to nearly zero, presumably because the depolarization of the membrane causes
rapid release of necessary intracellular ions.10 The development of this molecule is
significant, as it demonstrates a novel mode of action on the bacterial membrane. As it
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selectively permeabilizes bacterial as opposed to mammalian membranes, it provides a
precedent for the pursuit and development of tetramic acids—which act in a similar
fashion—as clinically relevant drugs.
Naturally-Occurring Tetramic Acids
Tetramic acids, or pyrrolidine-2,4-diones, are an important class of naturally occurring
molecules synthesized by numerous organisms. Members of this naturally occurring
class exhibit various significant biological activities, including antimicrobial activity. A
number of methods for their synthesis are present in the available literature. The pursuit
of compounds containing tetramic acid groups with therapeutic properties has been
undertaken for several decades, although comparatively few studies have been devoted
toward their potential as anti-infective agents.
A number of tetramic-acid containing molecules with demonstrated antimicrobial activity
have been isolated from a variety of natural sources. However, the types of substituents
on the common pyrrolidine ring (Figure 1.10) vary widely, as might be expected.
Wangun and Hertweck11 have reported the isolation of a small set of fungal isolates with
5-tyrosyl and 3-(dimethylnonyl)acetyl substitution; activity against Mycobacterium
vaccae was observed. Equisetin (Figure 1.11), first isolated by Burmeister et al.,12 was
first shown to be effective against several species of gram-positive bacteria, but not
against the majority of tested Gram-negative bacteria. The compound trichosetin (Figure
1.11), isolated by Marfori et al.,13 is an N-desmethyl homolog of equisetin containing a 5(ethanol) and 3-[1,6-dimethyl-2-propenyl 1,2,4-α,5,6,7,8,8-α octahydronaphthyl acyl]
substituent and, notably, having activity against S. aureus and Bacillus subtilis at
nanogram concentrations. The actinomycete derivatives Bu-2313A and B (Figure 1.11)
have demonstrable activity against the common skin pathogens Streptococcus pyogenes
(S. pyogenes) and Propionibacterium acnes,14 particularly the former.
Streptolydigin (Figure 1.11), a bacterial isolate, has been shown to inhibit RNA
polymerase in a fashion similar to the rifamycin compounds currently in clinical use;15 as
a consequence, it indirectly inhibits protein biosynthesis. Examination of its method of
action has revealed that although it acts faster at inhibiting RNA polymerization and
pyrophosphate exchange with ribonucleotide triphospates, both its pyrophosphate
exchange sensitivity and inhibitory capacity are weaker by a factor of approximately one
hundred.15 The structurally similar compound tirandamycin16 (Figure 1.11) also inhibits
Escherichia coli-derived RNA polymerase, but is not selective in that it also inhibits
mammalian RNA polymerase16 and mammalian mitochondrial respiration.17 Both
compounds demonstrate activity against several Gram-positive but not Gram-negative
bacteria, with bacteria of the Bacteroides genus being the only Gram-negative
exception.18
The melophlins, a sizable group of 3-acyl tetramic acids, (Figure 1.11), are (chiefly)
derived from the marine sponge Melophlus sarassinorum; at least nineteen such
compounds have been isolated.19-21 Their structures are similar in that they are all N-
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methylated, and possess either an H or CH3 substitution at the C-5 position; their key
differences are the length of the main alkyl chain (C12 to C16, including carbonyl) of the
3-acyl substituent and the position of the chain’s branching. Some of the melophlins
have biological properties, including cytotoxic (translating to potential anticancer drugs)
and antibacterial activity; the latter category includes melophlins C and G, which both
have demonstrable activity against Bacillus subtilis and S. aureus.22
A potential biological function of compounds with the tetramic acid moiety was proposed
by Kaufmann et al.,23 in which an autoinducer N-acylhomoserine lactone produced by the
Gram-negative bacterium Pseudomonas aeruginosa unexpectedly underwent aqueous
solvent-promoted rearrangement to a tetramic acid moiety. Both the precursor molecule
and the tetramic acid product (Figure 1.11) exhibited inhibitory activity against nine
different species of Gram-positive bacteria, including several strains of the Gram-positive
bacterium Bacillus cereus. However, no notable activity against Gram-negative species
E. coli or Salmonella typhimurium was observed. It was proposed that the MOA of this
product is similar to that of reutericyclin (see below); namely, it functions as an
ionophore and dissipates the bacterial transmembrane difference of pH, leading to cell
lysis.23,24 It also exhibits a high inhibitory constant due to ready penetration of the cell
membrane via its high lipophilicity.23,24
It should be noted that that these natural products were, albeit with exceptions, found to
be considerably more active against Gram-positive bacteria than Gram-negative bacteria.
The most likely explanation is that tetramic acid compounds are unlikely to penetrate
fully the outer lipopolysaccharide layer of Gram-negative bacteria in order to reach the
bacterial inner membrane.
Tetramic Acid Structure-Activity Relationship Investigations
Numerous syntheses of products containing tetramic acid moieties have been undertaken,
several of which have been directed toward the synthesis of natural products; these
syntheses may have a use in initiating optimization of the structure-activity relationships
exhibited by natural products. Tetramic acids not found in nature also comprise a portion
of syntheses undertaken thus far, although comparatively few studies have focused on the
SAR of substitutions. A number of natural products, including those mentioned above,
possess a diene chain connected to the 3-acyl group. A study by Rosen et al.25
investigated the effects of varying terminal aromatic groups on this 3-dienoyl substituent
in an effort to mimic the RNA polymerase inhibitory activity of streptolydigin and
tirandamycin A; these synthesized compounds either lacked C-5 or N-1 substitution or
were methylated at these positions. The noted SAR was that N-methylation provided
only a minor reduction in minimum inhibitory concentration, whereas C-5 methylation
dramatically weakened activity. An acyclic terminal functional group had far weaker
activity than an aromatic ring, as well. Toda et al.14 tested the effects of substitution at
the tetramic acid’s C-5 position on the aforementioned Bu2313-A and B, and found that
functionalities that were electron-withdrawing or larger than ethyl tended to have reduced
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activity against Propionibacterium acnes and Streptococcus pyogenes, particularly the
latter.
Attention should be drawn to the fact that the active compounds noted above lack
extensive substitution on the N-1 position; rather, all of them possess an N-H or N-CH3
functionality. They also typically possess 3-acyl substitution, frequently with either
unsaturated alkyl chains or a double bond at the carbon β to the carbonyl carbon. This
fact leaves the question open as to the potential, if any, of variations on substitutions at
the N-1 position. Yendapally et al.1 tested the effectiveness of 3-acyl tetramic acids
without substitution on the 3-acetyl functional group, and with varied N- and 5substitutions. A trend found in the activity of this series of compounds was that
lipophilic functional groups (long alkyl chains or aromatic and cyclic hydrocarbons) at
the N-position conferred the greatest antibacterial activity, although the leucine,
isoleucine, valine, and phenylalanine-based lipophilic side chains at the 5-position
conferred few differences in potency relative to each other.1
Synthetic Methods for Tetramic Acids
Biosynthesis of tetramic acids is most often stereospecific, with the following general
assembly procedure: The N-1, C-5, and C-4 positions on the ring are most commonly
derived from an amino acid (with the 5-position substituted with the amino acid side
chain), while the C-2 and C-3 positions are provided from acetate, which, in the case of
3-polyenoyl tetramic acids, is connected to preformed polyketides.26
Assembly of the 2,4-pyrrolidine diketone ring itself and introduction of varied
substituents at the 1-, 3-, and 5-positions are the main challenges faced in synthesis of
analogues. Toward this end, a number of synthetic methods have been devised.
Although numerous methods of introducing 3-substituents are available, a great many
bioactive tetramic acids possess 3-acyl functional groups, and it is these that are most
relevant to the current project. As such, the following discussion of synthetic methods
will be limited to those that produce the 3-acyl ring component.
The most common method of synthesis of the 3-acyl substituted ring is a version of the
Dieckmann condensation (Figure 1.12), involving base-promoted intramolecular Cacylation of N-acetoacetyl α-amino esters.27 (Competitive reactions involving other
acidic protons in the molecule would not be expected due to steric hindrance.) This
condensation typically takes place in protic solvent with a strong base, such as sodium
methoxide or potassium tert-butoxide (Scheme W; Figure 1.13).28 The chief problem
with this method, however, is that racemization at C-5 is common, as the C-5 hydrogens
are acidic (a condition stemming from their proximity to the electron-withdrawing
heteroatom and C-4 carbonyl) and can be readily removed under the strongly basic
conditions needed for the condensation. A few methods exist for generation of the
acetoacetyl α-amino esters, including—if the desired final tetramic acid is to be
unsubstituted at C-5—condensation of an alkylaminoacetonitrile with diketene; the
molecule can be converted to a lithium enolate and cyclized (Scheme X; Figure 1.13).29

12

O

O

R2

N

O

ROH

R2

N

H

O

O

O

O

H
R1

O

-OR

R1

O
O

O

O
R2

3

5

O

N

CH3OH

R2

OH

4

N

2

1

O

R1

R1

Figure 1.12. Lacey-Dieckmann Condensation Mechanism.

13

O
R

OR1
N

R2

R3
O

R2

O

N

OH
O

Scheme W

CN +

N
H

R3

Base

O

CN

O
R

O

R

R

O

n-BuLi

N
O

R

O

N

Scheme X
R

OH
O
R

O

O
R

O
+
(EtO)2P

OR1
NH2

O

HN

Δ

O

Scheme Y
R

O

NaOR
ROH
O
P(OEt)2

O

O
O

R

R

OR1

HN

NH2

HN

H3CC(=O)Cl HN
O

BF2
O

R1

NaHDMS
O

C7H15

O

O
HN
O

R1O

R
O

H2
Pd/C

O
Ph3P

BF3.OEt2

P(OEt)2

O
HO

O

OR1

O

O

Ph3P=C=C=O

R

O

HN

OR1

O

N

Cl

Scheme Z

O

R''
HO

Figure 1.13. Synthetic Pathways to 3-Acyl Tetramic Acids.

14

The N-acetoacetyl ester intermediates can also be generated by reaction of α-amino esters
with a diethylphosphonate acetone diketene adduct, followed by Dieckmann
condensation (Scheme Y; Figure 1.13). An advantage of this method is that it allows
Wadsworth-Emmons olefination to be performed subsequent to ring formation, if the
final molecule is to be a 3-dienoyl compound.30 A reported synthesis using an
acetoacetyl ester attached to a solid support noted near-quantitative yield, but made no
mention of stereoselectivity.31 Alternative protocols for ring formation require
subsequent 3-acylation. One such method, employed by Jouin et al.,32 employs
Knoevenagel condensation of α-amino acids with Meldrum’s acid, followed by heating to
cause intramolecular amidation with elimination of acetone and carbon dioxide. Lewis
acids, such as boron trifluoride or titanium tetrachloride, can couple acyl chlorides to the
ring.
An additional method of stereospecific ring formation uses a domino reaction sequence
wherein (triphenylphosporanylidene)ketene (Ph3P=C=C=O) is added across the terminal
amine of a chosen amino acid precursor to form active agents that rapidly undergo intraWittig reaction to form the tetramic acid ring (Scheme Z; Figure 1.13) .26,33 This method
is largely free of C-5 epimerization and can be performed under pH-neutral conditions.
The pathway toward ring formation without inclusion of the 3-acyl substituted tetramic
acids involves synthesis of the core ring, followed by 3-acylation. The known methods
for acylation, however, each suffer limitations on applicability in the presence of various
functional groups.26 The 4-O acylation of the ring with the desired carboxylic acid,
followed by a shift to the C-3 position, is accomplished by addition of the carboxylic acid
along with dicyclohexylcarbodiimide (DCC) and 4,4-dimethylaminopyridine (DMAP), as
initially reported by Hori et al.34 Reaction of the completed N-methyl, 3-unsubstituted
tetramic acid ring with thallous ethoxide, followed by acetyl fluoride, was reported to
yield 3-acetyl product; however, analogous reaction with acyl fluorides with longer
chains tended to give 4-O-acylated product instead.29
Reutericyclin Properties and Synthetic Approaches
Reutericyclin (Figure 1.14) is a natural product of significant interest, as it exhibits
antimicrobial activity in a fashion somewhat different from known antibiotics. The
compound, isolated from Lactobacillus reuteri, is found in sourdough bacterial colonies,
and has demonstrable bactericidal activity against other microbial residents. In a fashion
similar to organic acids used in food preservation,24 reutericyclin acts as a proton
ionophore and selectively dissipates bacterial cell membrane ΔpH, leading to reduced
chemopotential energy (necessary for ATP biosynthesis and active transport of
molecules) and eventual cell death. (The pKa of reutericyclin is in the range of 2 to 3.24)
It is active against Gram-positive bacteria, but not Gram-negative species; the production
of reutericyclin is thought to give the bacterium a competitive advantage against rival
species.35 The molecule’s amphiphilic nature is thought to allow it to penetrate the cell
lipid layer while acting as a depolarizing agent via its tetramic acid ring. As L. reuteri is
a frequent resident of human and animal intestinal microflora, as well as food
preparations,36 it represents a possible lead compound for safe antimicrobial agents.
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Several synthetic routes to reutericyclin have been devised, with varying degrees of
success; these routes have been mentioned above and are outlined in Figure 1.15. The
first synthesis, as noted by Böhme et al,37 employed the aforementioned method of
cyclization of N-acylated amino acid with Knoevenagel condensation with Meldrum’s
acid, followed by heat-promoted cyclization32 and 3-acylation catalyzed by titanium
tetrachloride; the final step caused racemization at the C-5 position (Scheme X, Figure
1.15). A more successful synthetic route employed N-acetoacetylation with N(hydroxysuccinimidyl)acetoacetate followed by Dieckmann condensation with sodium
ethoxide, then N-acylation promoted by butyllithium; the final compound was produced
in 80% enantiomeric excess (ee) (Scheme Y, Figure 1.15).37 The most effective chiral
synthesis employed the domino Wittig sequence described above,26 employing Disoleucine benzyl ester and Ph3=C=C=O to cyclize the ring, followed by boron
trifluoride-promoted acylation and ultimate N-deprotonation/acylation, to produce
reutericyclin in 95% ee (Scheme Z, Figure 1.15).26
Having explored the mechanism of action of currently available antimicrobial agents and
surveyed the potential of existing tetramic acids, I will, in the next chapter, detail how
knowledge of the structure-activity relationship of tetramic acids, and methods for
synthesizing them, may be used to achieve the goal of developing active compounds with
an improved safety profile.
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Chapter 2. Synthesis, Characterization, and Evaluation of Substituted Tetramic
Acid Compounds as Antibacterial Agents

Introduction
The current series of compounds was based on a previously synthesized series of
antibacterial tetramic acids by Yendapally et al.1,2 in which a set of 3-acetyl tetramic acids
resembling the natural antibiotic reutericyclin was made. These compounds possessed
varying amino acid-derived 5-substitutions (phenylalanine, leucine, isoleucine, and
valine). Several N-substituents, which were more stable to enzymatic degradation than
the N-acyl substituent of reutericyclin, were incorporated into these compounds as well.
The tested compounds with the most potent antibacterial activity were, in general, those
with highly lipophilic N-substituents; these substituents were theorized to be effective at
penetrating bacterial cell membranes. Although these compounds exhibited potent
antibacterial activity in vitro, concerns arose about their cytotoxicity, particularly a
hemolytic effect on human red blood cells, which was thought to stem from a
combination of the membrane-penetrating capacity imparted by the highly lipophilic N1and C5-substituents and the acidic nature of the tetramic acid ring.2 In light of these facts,
in this study, different 5-substituents generated from polar and basic amino acids were
employed in an effort to balance the negative charge of the acidic tetramic acid ring and
confer greater amphiphilicity, thus altering interaction with mammalian membranes. The
working hypothesis is that reduction of eukaryotic membrane damage could reduce
clinical side effects such as skin irritation (if used topically) or hemolytic anemia (if
administered intravenously). It is worth noting that many non-lytic membrane-active
antibiotics are amphiphilic, perhaps most notably daptomycin. A novel series of 5substituted tetramic acids was synthesized, and the compounds were tested for their
antimicrobial efficacy and hemolytic activity.
Results and Discussion
Synthetic Evaluation
The synthetic route utilized for this project (Figure 2.1), adapted from the protocol of
Yendapally,2 was chosen because of its established effectiveness in synthesizing 3-acyl
tetramic acids with nonpolar functional groups at the ring’s N and C-5 positions.1,2
Based on the antimicrobial activity of these prior compounds, the N-substituted
functional groups expected to confer the strongest activity were 4-phenylbenzyl (a),
myrtenyl (b), and decyl (c). 4-Ethylbenzyl (d) and 4-methoxybenzyl (e) (Figure 2.1) were
also used to test the effect of varying the para-substituent on the benzyl group, relative to
4-phenylbenzyl. After completion of the synthesis of these compounds, preliminary
antimicrobial and hemolytic studies were performed. Based on these findings, the
myrtenyl group, which resulted in minimal hemolysis compared with activity against
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S. aureus, was selected to be paired with the tyrosine side chain as a different polar Nsubstituent to produce compound 6 (Figure 2.1), via the same synthetic scheme. In the
initial synthetic step for all the compounds, amino acid (tyrosine or N-Boc lysine) methyl
ester hydrochloride was N-substituted by reductive amination with aldehydes 1a-e and
Et3N as basic catalyst in anhydrous THF, using anhydrous MgSO4 to maintain anhydrous
conditions. The resulting imine intermediates were reduced with NaBH4 in methanol to
form secondary amines, in total yields between 29.6-82.9%. The secondary amine
products 2a-f were acylated with diketene in CH2Cl2 at reflux, employing Et3N in
catalytic amount, to form N-acetoacetyl-α-amino esters in yields between 36.2-79.0%.
To form the tetramic acid rings, the N-acetoacetyl- α-amino esters 3a-f were cyclized via
Lacey-Dieckman condensation27 with sodium or potassium t-butoxide in t-butanol (these
bases were chosen for their reduced tendency to cause isomerization)28 to give nearly
quantitative yields. The rather high observed yields for these compounds probably derive
from the presence of a remnant of the reactant, as the reaction mixtures were subjected to
aqueous/organic extraction but not chromatography. These tetramic acids 4a-f were
tested for antimicrobial activity. For further testing, the Boc group was, as per the
procedure of Rakesh et al.,38 removed from the N-Boc lysine-derived tetramic acids with
TFA in THF to form primary amines 5a-e as their TFA salts. The TFA cleavage step
proved to be the most difficult, with incomplete reaction being the norm and frequently
requiring a second run of the reaction before MS testing demonstrated the disappearance
of the starting material.
The main divergence of structure, compared with the prior series, was the functional
group at the C-5 position. Greater difficulty was expected in the use of polar amino acid
starting materials, as they had potential to interfere with each of the three main steps (Nalkylation, N-acylation, and ring closure), and to make purification difficult, as highly
polar functional groups tend to adsorb strongly onto silica-based chromatography
columns. These difficulties were circumvented by the use of N-Boc-protected lysine;
however, cleavage of the protecting group with trifluoroacetic acid proved difficult,
necessitating comparatively long reaction times and repeated evaporation to remove the
material, and forming salts rather than the desirable free base. The final products,
whether protected or deprotected, were also highly polar and resistant to elution on thinlayer silica plates, and so silica-based flash chromatographic purification was not
attempted. An inherent difficulty in assigning NMR peaks to the products was also
encountered due to the presence of tautomers in the N-acylacetoamine intermediates 3a-e
(Figure 2.1) and in the ultimate tetramic acid products. There are a total of nine possible
tautomers of 3-acyl tetramic acids,39 but only four, shown in Figure 2.2, are present in
detectable concentrations. They consist of internal and external pairs which interconvert
too rapidly to be detected on the NMR time scale, although the rate of conversion
between internal and external pairs is sufficient to determine their ratio of concentration
if their NMR signals are distinguishable.39 Intramolecular hydrogen bonding, as shown
in Figure 2.2, would be expected to improve the stability of the enol tautomers A and C
of the 3-acyl group. For these reasons, mass spectrometry was the most useful technique
to determine the presence or absence of the final product. A similar use was made of
reversed-phase HPLC, which was invaluable in determining the purity of the ultimate
reaction mixtures, as the tetramic acid ring acts as a UV chromophore.
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Biological Evaluation
Ultimately, eleven tetramic acid compounds were synthesized and tested against a small
panel of clinically relevant bacteria: Staphylococcus aureus (methicillin-susceptible),
Enterococcus faecalis, and Bacillus anthracis. No Gram-negative bacteria were tested,
as tetramic acids are generally inactive against them. This is most likely due to a lack of
penetration of the outer membrane of Gram-negative bacteria, although, a few exeptions
to this trend have been noted;1,2,23 consequently, Gram-negative bacteria would not be
expected to serve as reliable negative controls. Tables 2.1 and 2.2 illustrate the structureactivity relationship of the current series, with compounds 867 and 1138 included as a
comparison of the compounds with the strongest activity from the prior series.1,2
Among the compounds with the Boc protecting group, the predicted activity trends were
nearly the opposite of the outcome. The biphenyl and myrtenyl functional groups of 4a
and 4b conferred essentially no activity against S. aureus or E. faecalis, although 4a had
moderate activity against B. anthracis. The other compounds possessed greater activity
against all the bacteria tested, although the N-decyl group (4c), surprisingly, averaged no
more potency than the aromatic compounds (4d-e). These findings are in contrast to the
findings of the earlier study,1,2 in which the myrtenyl and decyl N-substituents offered
among the greatest potency.
The primary amine compounds (Table 2.2) had greater activity than the Boc-protected
compounds in the majority of cases, although it should be noted that the deprotected
compounds typically had lower purity due to some remaining starting materials. As with
the parent series,1,2 unlike with the Boc-protected class, the most effective compounds
possessed a bicyclic ring derived from myrtenyl (5b) or a long-chain alkyl group at N-1
(5c). Although the presence of a primary amine imparted generally greater activity
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Table 2.1: Structures and Activities of Tetramic Acids.
General Structure
O
OH
R2

No.
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0.8
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25
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O
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O
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MIC: Minimum inhibitory concentration. MSSA: Methicillin-susceptible Staphylococcus aureus 8325; EF: Enterococcus faecalis
ATCC 33186; BA: Bacillus anthracis Sterne 34F2. Mol. Wt.: Molecular weight. CLogP was calculated using ChemDraw Ultra,
Version 7.0 software by Cambridge Soft.
†Source: Yendapally, R.; Hurdle, J. G.; Carson, E. I.; Lee, R. B.; Lee, R. E., N-Substituted 3-acetyltetramic acid derivatives as
antibacterial agents. J. Med. Chem. 2008, 51, (5), 1487-1491.1
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Table 2.2. Structures and Activities of Tetramic Acids.
General Structure
O
OH
R2

*

N
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O

No.
867†

R1

R2

9
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MIC (µg/mL)
MSSA
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Mol.
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0.4
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0.8
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H2N

100
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H2N

25
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346.46
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H2N
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H2N
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MIC: Minimum inhibitory concentration. MSSA: Methicillin-susceptible Staphylococcus aureus 8325; EF: Enterococcus faecalis
ATCC 33186; BA: Bacillus anthracis Sterne 34F2. Mol. Wt.: Molecular weight. CLogP was calculated using ChemDraw Ultra,
Version 7.0 software by Cambridge Soft.
†Source: Yendapally, R.; Hurdle, J. G.; Carson, E. I.; Lee, R. B.; Lee, R. E., N-Substituted 3-acetyltetramic acid derivatives as
antibacterial agents. J. Med. Chem. 2008, 51, (5), 1487-1491.1
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relative to the Boc-protected compounds, the effect was less pronounced for the
compounds with N-1 benzylic substitution (5a, 5d-e). With respect to the bacterial
species, the compounds as a whole tended to be most effective against Bacillus anthracis,
but the activity trends were generally similar for each of the three bacterial species tested.
Hemolytic trends were far clearer than antibacterial activity trends (Figure 2.3); at the
highest concentration of compound used (100 µg/mL), the primary amino lysine-derived
compounds were, as hypothesized, less hemolytic than the Boc-protected compounds
(except in the case of the 4-ethylbenzyl pair 4d and 5d). At lower concentrations, the
hemolytic activities were considerably more similar for the protected and deprotected
pairs. A similar statement can be made for compound 6; namely, that despite its lack of a
basic functional group that has potential for carrying a positive charge, the presence of a
hydrogen bond donor may be sufficient for reducing erythrocyte lysis without apparent
loss of antimicrobial activity.
A comparison between the current series and the earlier series illustrates some significant
changes. The antimicrobial activities of the present compounds, which possess polar
functionalities at C-5, are considerably lower than the earlier compounds 867 and 11381,2
possessing an isobutyl substituent at C-5 (Table 2.1). However, a comparison between
the present and previous compounds reveals a dramatic reduction in hemolysis at 100
µg/mL (Figure 2.3). The reduced antimicrobial activities of these molecules may be
explainable in terms of reduced affinity for the membrane by the lipophilic N-functional
groups. The free-amino compounds should be, hypothetically, amphipathic due to the
acidic diketone paired with basic primary amine. In all instances, the lipophilic Nsubstituent is likely to partition into the Gram-positive bacterial plasma membrane,
whether the tetramic acid has an overall neutral or negative charge. If the ring is
amphipathic, however, the N-substituent’s position in the membrane becomes less
energetically stable due to positive interactions with the membrane’s prevalent internal
negative charges, and the tetramic acid is less able to maintain the position it requires for
its depolarization of the membrane.
It may appear that reduction of hemolytic activity is incompatible with improvement of
antibacterial activity. However, the mechanism of action on red blood cells membranes
is thought to be different from that on bacterial in that bacteria rely on membrane
potential difference for energy, whereas eukaryotic cells rely on mitochondria; therefore,
ionophores would be expected to have weaker effects on eukaryotic cells. Also, it has
been suggested that hemolysis stems from membrane solubilization rather than
ionophoric activity. As such, there is potential for designing tetramic acids with selective
activity, which could translate to clinically safe antimicrobials.
Conclusions
The chosen synthetic route led to the successful synthesis of several tetramic acids with a
polar functional group at the C-5 position. The hemolytic activity of the compounds
synthesized was, as hypothesized, lowered due to the inclusion of a polar substituent at

24

100
90
80
70

% Hemolysis

100 ug/mL

60

10 ug/mL
1 ug/mL

50
40
30
20
10
0
867

1138

4a

5a

4b

5b

4c

5c

4d

5d

4e

5e

6

Compound

Figure 2.3. Hemolysis Chart. % Hemolysis: Measured as optical density at 540 nm of supernatant of suspended erythrocyte
samples to which a quantity of drug sufficient to provide the necessary concentration had been added and incubated. Negative
controls were non-hemolytic antibiotics ampicillin and doxycycline; positive control was Triton-X (induced 100% hemolysis).

25

C-5. Their antimicrobial activity, however, was weakened, potentially for the same
reason. Possible ways of increasing the antimicrobial potency may include alkylation of
the free amino compounds to improve lipophilicity and penetration into bacterial
membranes. Also, as compound 6 exhibited antimicrobial activity comparable to several
of the free amino compounds, and fairly low hemolytic activity, the synthesis of other
compounds with similar polar but nonbasic substitution may merit further investigation.
Future studies will be required to expand the tetramic acid series, maintaining low
hemolytic activity while increasing antimicrobial activity.
Experimental Section
Chemistry
General Synthetic Scheme
Amino acid (N-Boc L-lysine or L-tyrosine) methyl ester hydrochloride was N-substituted
by reductive amination with aldehydes 1a-e and Et3N in anhydrous THF in the presence
of MgSO4 to maintain anhydrous conditions. The resulting imine intermediates were
reduced with NaBH4 in methanol. The resulting secondary amines 2a-f were acylated
with diketene in CH2Cl2 at reflux, employing Et3N in catalytic amount. To form the
tetramic acid rings, the acetoacetyl amides 3a-f were cyclized via Lacey-Dieckman
condensation26 with sodium or potassium t-butoxide in t-butanol (these bases were
chosen for their reduced tendency to cause isomerization). These tetramic acids 4a-f
were tested for antimicrobial activity. For further testing, the Boc group was removed
from the N-Boc lysine-derived tetramic acids with TFA in THF to form primary amines
5a-e as their TFA salts. The TFA cleavage step proved to be the most difficult, with
incomplete reaction being the norm and frequently necessitating a second trial before MS
testing demonstrated the disappearance of the starting material.
Experimental Methods
1

H NMR was performed on either a Varian Unity INOVA 500 MHz spectrometer or a
Bruker-ARX 300 MHz spectrometer. Mass spectra were recorded on a Bruker-Esquire
LC-MS using ESI. Flash chromatography was performed on a Biotage Horizon HPFC
system, employing Biotage FLASH 25 + M cartridges. Yields quoted are unoptimized.
HPLC1, HPLC2, HPLC3, and HPLC4 methods were followed using a Phenomenex
platinum C-18 reverse phase column (100Å, 50 x 4.6 mm) at ambient temperature, and a
flow rate of 1.0 mL min-1. HPLC1: Gradient: solvent A (0.1% TFA in water) and solvent
B (acetonitrile): 0-2.00 min. 100% A, 2.00-7.00 min. 0-100% B (linear gradient), 7.008.00 min. 100% B, 8.00-9.90 min. 100-0%B (linear gradient), 9.90-10.00 min. 0%B, UV
detection at 254 nm. HPLC2: Gradient: solvent A (0.1% TFA in water) and solvent B
(acetonitrile): 0-1.00 min 0-80% B (linear gradient), 1.00-7.5 min 80%-100% B (linear
gradient), 7.5-8.00 min 100% B, 8.00-9.00 min. 100-0% B (linear gradient), 9.00-10.00
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min. 100% A, UV detection at 254 nm. HPLC3: Gradient: solvent A (0.1% TFA in
water) and solvent B (acetonitrile): 0-2.00 min 35%B, 2.00-7.00 min 35-100%B (linear
gradient), 7.00-8.00 min 100%B, 8.00-9.00 min 100-35%B (linear gradient), 9.00-10.00
min 35%B, UV detection at 254 nm. HPLC4: Gradient: solvent A (0.1% TFA in water)
and solvent B (acetonitrile): 0-2.00 min 100%A, 2.00-17.00 min 0-100%B (linear
gradient), 17.00-18.00 min 100%B, 18.00-19.90 min 100-0%B (linear gradient), 19.9020.00 min 0%B, UV detection at 254 nm.
Solvents were purchased from Sigma-Aldrich and Fisher and used without further
purification. All reagents were provided by Sigma-Aldrich, except for L-tyrosine methyl
ester, which was provided by EMD Biosciences.
General procedure for preparation of secondary amines (2a-d.) The L-amino acid
methyl ester hydrochloride salt (1 equiv) was dissolved in anhydrous THF, and to it were
added aldehyde (2 equiv), Et3N (1 equiv), and MgSO4 (1.7 equiv). The mixture was
allowed to stir at room temperature under argon for a minimum of 6 h, then filtered and
evaporated in vacuo to yield the crude imine. The crude imine was directly dissolved in
methanol, and to it was slowly added NaBH4 (2 equiv). The reaction mixture was
quenched with excess 1 N NaOH and extracted with ethyl acetate, then dried over
Na2SO4 and concentrated in vacuo. The crude secondary amine was then purified by
flash chromatography via a petroleum ether/ethyl acetate gradient.
6-tert-Butoxycarbonylamino-2-(4-phenyl-benzylamino)-hexanoic acid methyl ester
(2a). To a solution of L-lysine methyl ester hydrochloride (0.5 g, 1.68 mmol) in
anhydrous THF (10 mL) were added biphenyl-4-carboxaldehyde (0.614 g, 3.37 mmol),
Et3N (235 μL, 1.68 mmol), and MgSO4 (0.345 g, 2.86 mmol), and left to stir at rt under
argon overnight. The reaction mixture was filtered, then concentrated in vacuo to yield
the crude imine. The crude imine was then dissolved in methanol, and NaBH4 (0.127 g,
3.37 mmol) added to it slowly. The mixture was stirred at rt for 30 min, then quenched
with excess 1 N NaOH and extracted with ethyl acetate, then worked up as in the general
procedure to yield 0.531 g (73.9%) of 2a as syrup. 1H NMR (500 MHz, CD3OD): δ 1.24
(1H, t, J = 7.25 Hz), 1.32-1.41 (2H, m), 1.41-1.49 (11H, m), 1.62-1.71 (2H, m), 2.01 (1H,
s), 3.02 (2H, t, J = 6.25 Hz), 3.29 (1H, t, J = 7.75 Hz), 3.65 (1H, d, J = 13.5 Hz), 3.71
(3H, s) 3.80 (1H, d, J = 13 Hz), 4.10 (1H, q, J = 7.17 Hz) 7.30-7.34 (1H, t, J = 7.25 Hz),
7.38-7.44 (4H, dd, J = 7.67 Hz), 7.55-7.61 (4H, dd, J = 7.5 Hz). ESI-MS: 449.3 (M +
23).
6-tert-Butoxycarbonylamino-2-[(6-methyl-bicyclo[3.1.1]hept-2-en-2-ylmethylene)amino]-hexanoic acid methyl ester (2b). To a solution of L-lysine methyl ester
hydrochloride (0.40 g, 1.35 mmol) in anhydrous THF (10 mL) were added (1R)-(-)myrtenal (410 μL, 2.70 mmol), Et3N (225 μL, 1.62 mmol), and MgSO4 (0.276 g, 2.29
mmol), and left to stir at rt under argon for 10.5 h. The reaction mixture was filtered,
then concentrated in vacuo to yield the crude imine. The crude imine was dissolved in 10
mL methanol, then 0.102 g NaBH4 (2.70 mmol) was added slowly. The mixture was
stirred at rt for 30 min, then worked up as described in the general procedure to yield 0.21
g (39.5%) of 2b. 1H NMR (500 MHz, CDCl3): δ 0.83 (3 H, s), 1.14 (1H, d, J = 9Hz),
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1.27-1.31 (4.4H, m), 1.34-1.40 (2.37H, m), 1.41-1.52 (11.88H, m), 1.54-1.67 (2.28H, m),
1.67-1.72 (1.14H, s), 2.09 (2H, d, J = 5Hz), 2.18-2.24 (2H, q, J = 17.3Hz), 2.34-2.39
(1.06H, m), 2.95 (1H, d), 3.07-3.11 (3H, m), 3.24 (1H, t), 3.72 (3H, s), 4.66 (0.83H, s),
5.36 (1H, s). ESI-MS: 395.3 (M + 1), 417.3 (M + 23).
6-tert-Butoxycarbonylamino-2-decylamino-hexanoic acid methyl ester (2c). To a
solution of L-lysine methyl ester hydrochloride (0.91 g, 3.1 mmol) and MgSO4 (0.50 g,
4.2 mmol) in anhydrous THF (25 mL) were added decanal (0.38 mL, 2.0 mmol), and
Et3N (0.59 mL, 4.2 mmol), and the reaction was left to stir at rt . The reaction mixture
was filtered, then concentrated in vacuo to yield the crude imine. The crude imine was
then dissolved in methanol, and NaBH4 (0.153 g, 4.04 mmol) added to it slowly. The
mixture was stirred at rt for 30 min, quenched with excess 1 N NaOH and extracted with
ethyl acetate, then worked up as described in the general procedure to yield 0.671 g
(82.9%) of 2c. 1H NMR (500 MHz, CDCl3): 0.88 (3H, t, J = 6.5 Hz), 1.18-1.33
(13.94H, m), 1.32-1.40 (1.8H, m), 1.38-1.53 (11.94H, m), 1.57-1.68 (2.17H, m), 2.412.48 (1 H, m), 2.50-2.58 (1H, m), 3.04 (1.15H, s), 3.05-3.14 (1.71H, m), 3.20-3.26 (1H, t,
J = 6.25Hz), 3.72 (3H, s), 4.87 (1H, bs). ESI-MS: 401.4 (M + 1), 423.3 (M + 23).
6-tert-Butoxycarbonylamino-2-(4-ethyl-benzylamino)-hexanoic acid methyl ester
(2d). To a solution of L-lysine methyl ester hydrochloride (0.40 g, 1.35 mmol) in
anhydrous THF (10 mL) were added 4-ethylbenzaldehyde (369 μL, 2.70 mmol), Et3N
(188 μL, 1.68 mmol), and MgSO4 (0.276 g, 2.29 mmol), and left to stir at rt under argon
for 9 h. The reaction mixture was filtered, then concentrated in vacuo to yield the crude
imine. The crude imine was then dissolved in methanol (10 mL), and NaBH4 (0.1-2 g,
2.70 mmol) added to it slowly. The mixture was stirred at rt for 30 min, then quenched
with 7 mL of 1 N NaOH and extracted with 3 x 10 mL ethyl acetate, then worked up as
described in the general procedure to yield 0.248 g (48.6%) of 2d as gel. 1H NMR (500
MHz, CD3OD): δ 1.28 (3H, t), 1.34-1.41 (2.41H, m), 1.41-1.56 (11.19H, m), 1.67-1.77
(2H, m), 2.66-2.71 (2H, q), 3.06-3.10 (2H, t), 3.31-3.35 (1H, t), 3.64-3.67 (1H, d), 3.77
(3H, s), 3.77-3.81 (1H, d), 7.20-7.23 (2H, d), 7.28-7.31 (2H, d). ESI-MS: 401.3 (M +
23).
6-tert-Butoxycarbonylamino-2-(4-methoxy-benzylamino)-hexanoic acid methyl ester
(2e). To a solution of L-lysine methyl ester hydrochloride (0.40 g, 1.35 mmol) in
anhydrous THF (15 mL) were added p-anisidine (367 μL, 3.02 mmol), Et3N (188 μL,
1.35 mmol), and MgSO4 (0.276 g, 2.29 mmol), and left to stir at rt under argon for 6.25 h.
The reaction mixture was filtered, then concentrated in vacuo to yield the crude imine.
The crude imine was then dissolved in methanol (15 mL), and NaBH4 (0.102 g, 2.70
mmol) added to it slowly. The mixture was stirred at rt for 30 min, then 0.050 g
additional NaBH4 added slowly, and the mixture stirred for an additional 1 h. The
reaction was then quenched with excess 1 N NaOH. Ethyl acetate was added, then the
mixture was evaporated to dryness, then reconstituted with methanol, water, and ethyl
acetate. The cloudy precipitate in the aqueous layer was drained off, then more water
added, and the precipitate drained off again. Finally, the solution was extracted with
ethyl acetate, allowing the precipitate to settle out of the organic layer, and the material
worked up as in the general procedure to yield 0.152 g (29.8%) of 2e. 1H NMR (300
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MHz, CD3OD): 1.23-1.53 (12.49H, m), 1.59-1.73 (1.79H, m), 2.94-3.10 (1.72H, m),
3.26 (0.83H, t, J = 11.2Hz), 3.52-3.68 (1.09H, m), 3.69 (0.75H, s), 3.73 (2.11H, s), 3.783.88 (2.90H, m), 6.83-6.99 (1.92H, m), 7.16-7.40 (2H, m). ESI-MS: 487.3 (M + 23)
2-[(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-amino]-3-(4-hydroxy-phenyl)propionic acid methyl ester (2f). To a solution of L-tyrosine methyl ester hydrochloride
(0.60 g, 2.6 mmol) and MgSO4 (0.778 g, 4.2 mmol) in anhydrous THF (15 mL) were
added (1R)-(-)-myrtenal (0.79 mL, 5.2 mmol), and Et3N (0.43 mL, 3.1 mmol), and the
reaction was left to stir at rt for 5 h. The reaction mixture was filtered, then concentrated
in vacuo to yield the crude imine. The crude imine was then dissolved in 15 mL
methanol, and NaBH4 (0.196 g, 5.18 mmol) added to it slowly. The mixture was stirred
at rt for 30 min, then quenched with 10 mL 1 N NH4Cl, concentrated under reduced
pressure, reconstituted with 10 mL water, and extracted with 3 x 25 mL ethyl acetate,
then worked up as in the general procedure to yield 0.576 g (67.5%) of 2f. 1H NMR (500
MHz, CD3OD): δ 0.82 (0.19H, s), 0.84 (3H, s), 1.14 (1H, d, J = 8.5 Hz), 1.27 (0.19H, s),
1.29 (3H, s), 2.05-2.11 (2H, m), 2.21-2.32 (2H, q, J = 14.8 Hz), 2.37-2.43 (1H, m), 2.86
(2H, d, J = 6.5 Hz), 2.98 (1H, d, J = 14 Hz), 3.11 (1H, d, J = 13.5 Hz), 3.37 (2H, s), 3.49
(1H, t, J = 7 Hz), 3.63 (3H, s), 3.66 (0.17H, s), 5.34 (1H, s), 6.72 (2H, d, J = 8 Hz), 6.99
(2H, d, J = 9 Hz). ESI-MS: (+) 330.3 (M + 1), 352.2 (M + 23); (-) 328.0 (M - 1).
General procedure for N-acetoacetyl amino esters (3a-f). Secondary amine (2a-f) was
dissolved in CH2Cl2, to which 1 equivalent of 50% diketene in CH2Cl2 and 5 drops Et3N
were added. The mixture was allowed to reflux at 45°C for a minimum of 5 h, then
allowed to cool to rt and diluted with CH2Cl2, acidified with 1 N HCl, and extracted. The
organic layer was rinsed with water, dried with Na2SO4, filtered, and concentrated in
vacuo. The crude product was purified via flash chromatography, employing a petroleum
ether/ethyl acetate gradient.
6-tert-Butoxycarbonylamino-2-[(4-phenyl-benzyl)-(3-oxo-butyryl)-amino]-hexanoic
acid methyl ester (3a). To a solution of 2a (0.531 g, 1.24 mmol) in dichloromethane
were added 50% diketene in dichloromethane (210 μL, 1.24 mmol) and 5 drops of Et3N.
The mixture was allowed to reflux at 45°C overnight, then allowed to cool, diluted with
20 mL dichloromethane, quenched with 1 N HCl, and then the organic component
washed twice with water before being worked up as in the general procedure to yield
0.502 g (79.0%) of 3a as syrup. 1H NMR (500 MHz, CD3OD): δ 1.18-1.48 (13.12H, m),
1.70-1.86 (1H, m), 1.88 (1H, s), 1.93-2.10 (1.43H, m), 2.20 (1.13H, s), 2.3 (0.48H, s),
2.86-3.05 (2H, m), 3.37 (1.45H, s), 3.49-3.55 (0.73H, m), 3.60 (2.22H, d, J = 10.5Hz),
3.63-3.82 (0.89H, m), 4.37-4.51 (0.58H, m), 4.53-4.76 (2.35H, m), 4.85 (2.29H, s), 5.285.31 (0.32H, s), 7.30-7.48 (5H, m), 7.52-7.69 (4H, m). ESI-MS: 533.3 (M + 23).
6-tert-Butoxycarbonylamino-2-[1-(6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl)-2,4dioxo-pentylamino]-hexanoic acid methyl ester (3b). To a solution of 2b (0.210 g,
0.402 mmol) in dichloromethane (10 mL) were added 50% diketene in dichloromethane
(89.5 μL, 0.402 mmol) and 5 drops of Et3N. The mixture was allowed to reflux at 45°C
for 5 h, then allowed to cool to room temperature prior to adding 20 mL CH2Cl2, then 10
mL of 1 N NaOH, followed by 20 mL 1 N HCl. The organic layer was separated and
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washed with 2 x 10 mL water, and then, the combined aqueous portions were back
extracted with 2 x 20 mL CH2Cl2. The organic layers were then worked up as in the
general procedure to afford 0.12 g (47.1%) of 3b as a colorless oil. 1H NMR (500 MHz,
CDCl3): δ 0.83 (3H, d, J = 9 Hz), 1.12 (1.05H, t, J = 9.25 Hz), 1.24-1.27 (0.47H, d, J = 6
Hz), 1.29 (3H, s), 1.33-1.43 (2.10H, m), 1.41-1.47 (9.27H, m), 1.47-1.54 (2.15 H, m),
1.67-1.78 (1.87H, m), 1.90-1.99 (2.93H, m), 2.11-2.16 (1H, bs), 2.17 (0.77H, s), 2.2-2.34
(3.68, m), 2.38-2.44 (1H, m), 3.06-3.15 (2H, bs), 3.52-3.54 (1.33H, s), 3.55-3.63 (0.95H,
m), 3.68 (3H, s), 3.69-3.72 (0.38H, d, J = 11.5 Hz), 3.81-3.90 (0.94H, m), 4.68 (0.66H, t,
J = 7 Hz), 4.77-4.82 (0.29H, t, J = 7 Hz), 5.02 (0.32H, s), 5.32-5.37 (0.30, bs), 5.38-5.43
(0.62, bs). ESI-MS: 501.2 (M + 23).
6-tert-Butoxycarbonylamino-2-[decyl-(3-oxo-butyryl)-amino]-hexanoic acid methyl
ester (3c). To a solution of 2c (0.671 g, 1.68 mmol) in dichloromethane (35 mL) were
added 50% diketene in dichloromethane (0.28 mL, 1.68 mmol) and 10 drops of Et3N.
The mixture was allowed to reflux at 45°C for 7 h, then allowed to cool to rt, and diluted
with 40 mL CH2Cl2. To the mixture was added 10 mL of 1 N HCl; the aqueous and
organic layers were separated and the organic layer washed with 2 x 20 mL water. The
combined aqueous layers were then back extracted with 2 x 40 mL CH2Cl2. The reaction
mixture was then worked up as in the general procedure to yield 0.463 g (57.0%) of 3c as
a yellow amorphous solid. 1H NMR (500 MHz, CDCl3): δ 0.69-0.77 (3H, t, J = 7 Hz),
1.02-1.42 (28.34H, m), 1.42-1.76 (1.09H, m), 1.76-1.83 (1H, s), 1.83-1.97 (1.08H, m),
2.07 (0.77H, s), 2.11 (2H, s), 2.86-3.04 (2.23H, m), 3.10-3.22 (0.89H, m), 3.31-3.48
(1.34H, m), 3.48-3.60 (3.18H, m), 3.78-3.83 (0.44H, bs), 4.05-4.20 (0.58H, m), 4.41-4.52
(0.22H, m), 4.79-4.95 (0.80H, m). ESI-MS: 507.3 (M + 23).
6-tert-Butoxycarbonylamino-2-[(4-ethyl-benzyl)-(3-oxo-butyryl)-amino]-hexanoic
acid methyl ester (3d). To a solution of 2d (0.248 g, 0.655 mmol) in dichloromethane
(12 mL) were added 50% diketene in dichloromethane (111 μL, 0.655 mmol) and 5 drops
of Et3N. The mixture was allowed to reflux at 45°C for 7 h, then allowed to cool and
diluted with 15 mL CH2Cl2, then washed with 5 mL of1 N HCl, followed by 2 x 10 mL
H2O. The material was then worked up as in the general procedure. The material was
then reacted again, employing 90 µL (0.046 g, 0.545 mmol), of 50% diketene in
dichloromethane, several drops of Et3N, and 10 mL dichloromethane; the reaction
refluxed at 45°C for 10h, then cooled and diluted with 20 mL CH2Cl2 and washed with
10 mL 1 N HCl, followed by 2 x 10mL H2O and worked up as in the general procedure
without chromatography to give 3d in an overall yield of 0.186 g (61.4%). 1H NMR (500
MHz, CD3OD): 1.20-1.30 (3.69H, m), 1.30-1.44 (3.22H, m), 1.50 (9.42H, d, J = 28Hz),
1.68-1.85 (1.17H, m), 1.91 (0.63H, s), 1.95-2.09 (1H, m), 2.21 (1.18H, s), 2.31 (0.44H,
s), 2.60-2.71 (2H, m), 2.88-3.08 (2H, m), 3.53 (0.57H, s), (1.9H, ), 3.65-3.74 (0.50H, m),
3.75 (0.49H, s), 3.76-3.93 (0.31H, m),4.35-4.41 (0.42H, m) 4.46-4.72 (2.27H, m), 5.32
(0.13H, s), 6.36-6.52 (0.50H, m), 7.12-7.32 (4H, m). ESI-MS: 485.3 (M + 23).
6-tert-Butoxycarbonylamino-2-[(4-methoxy-benzyl)-(3-oxo-butyryl)-amino]hexanoic acid methyl ester (3e). To a solution of 2e (0.152 g, 0.399 mmol) in
dichloromethane (10 mL) were added 50% diketene in dichloromethane (67 μL, 0.399
mmol). The mixture was allowed to reflux at 45°C for 18 h; then, 13 drops of Et3N and
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an additional 67 µL diketene were added, and the reaction refluxed a further 24h at 45°C,
then allowed to cool to near room temperature. 10 mL of 1 N HCl were added to the
mixture, then 20 mL CH2Cl2. The organic layer was separated and washed with 2 x 10
mL water, then worked up as in the general procedure to afford 0.186 g (61.4%) of 3e.
1
H NMR (500 MHz): δ 1.10-1.54 (12.34H, m), 1.68-1.84 (0.93H, m), 1.90 (0.81H, s),
1.93-2.08 (1.2H, m), 2.13-2.32 (2.2H, m), 2.57-2.63 (0.5H, m), 2.87-3.02 (1.67H, m),
3.32-3.35 (0.5H, m), 3.37 (0.45H, s), 3.50-3.54 (0.47H, s), 3.56-3.63 (1.64H, m), 3.633.75 (0.89H, m), 3.75-3.89 (3.56H, m), 4.27-4.33 (0.34H, m), 4.38-4.64 (2.13H, m), 4.85
(2.45H, s), 4.90-5.04 (0.31H, m), 6.75-6.98 (2.1H, m), 7.16-7.34 (2H, m). ESI-MS:
487.3 (M + 23).
2-[(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-(3-oxo-butyryl)-amino]-3-(4hydroxy-phenyl)-propionic acid methyl ester (3f). To a solution of 2f (0.576 g, 1.75
mmol) in anhydrous CHCl3 (30 mL) were added 50% diketene in dichloromethane (296
µL, 1.76 mmol) and several drops of Et3N. The reaction was refluxed at 45°C for 9 h,
then allowed to cool to rt, diluted with 40 mL CHCl3 and extracted with 10 mL water
combined with 10 mL of 1 N HCl solution. The aqueous layer was extracted with 2 x 40
mL CHCl3, and the combined organic layers worked up as in the general procedure to
yield 0.287 g (39.7%) 3f as a brown gel. 1H NMR (500MHz, CD3OD): δ 0.82 (2.06H,
s), 0.84 (0.68H, s), 0.87 (0.13H, s), 1.09-1.13 (0.93H, m), 1.30 (3H, s), 1.92 (0.60H, s),
1.97-2.02 (0.88H, broad triplet, J = 5.25 Hz), 2.033 (0.12H, s), 2.06-2.10 (1.01H, bs),
2.15 (0.12H, s), 2.19 (0.18H, s), 2.21 (2.19H, s), 2.22-2.25 (0.63H, bs), 2.27-2.30 (0.56H,
bs), 2.30-2.34 (0.23H, bs), 2.38-2.44 (1 H, m), 2.99 (0.83H, d, J = 17 Hz), 3.03 (0.12H,
s), 3.07-3.15 (1H, m), 3.17-3.26 (1H, m), 3.37 (4.45H, s), 3.51-3.62 (1.36H, q, J = 15.2
Hz), 3.66 (0.62, s), 3.68 (2.09H, s), 3.70 (0.13H, s), 3.70-3.73 (0.48, bs), 3.74-3.77
(0.44H, bs), 4.29 (0.69H, dd, J = 5.17 Hz), 5.13 (0.18H, s), 5.23 (0.24H, s), 5.30 (0.66, s),
6.69-6.78 (1.89H, m), 7.01 (0.43H, d, J = 9Hz), 7.7.08 (1.48H, d, J = 8.5Hz). ESI-MS:
414.3 (M + 1), 436.3 (M + 23).
General procedure for formation of tetramic acids 4b-e and 6. To a flask containing
the diketone, 5 mL warmed t-butanol was added. The flask was kept at 40°C to prevent
the solvent from solidifying, and to it was added 3 equivalents of either sodium or
potassium tert-butoxide, gradually. The reaction mixture was stirred for 1 h, then water
and excess 1 N HCl solution were added. The neutralized mixture was extracted with
CH2Cl2, dried with Na2SO4, filtered, and concentrated in vacuo.
(4-[1-(4-phenyl-benzyl)-4-(1-hydroxy-ethylidene)-3,5-dioxo-pyrrolidin-2-yl]-butyl)carbamic acid tert-butyl ester (4a). A quantity of t-butanol was thawed, and was added
to 0.283 g of sodium t-butoxide. The base dissolved poorly in the solvent, but suspended
solid was added via Pasteur pipet into a flask containing 0.502 g 3a, kept stirring at 40°C.
Approximately half the base could be added to the reaction mixture; the amount of time
spent in the addition was approximately 40 min. To the reaction mixture was added
water and 1 N HCl, and the mixture extracted with CH2Cl2. Yield: 0.114 g, 24.2%.
1
H NMR (500MHz, CD3OD): δ 1.24 (0.73H, s), 1.26-1.39 (2.40H, m), 1.43 (9.24H, s),
1.72-1.80 (2H, m), 2.01 (0.29H, s), 2.46 (2.45H, s), 2.92-2.98 (2H, m), 3.37 (9.70H, s),
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7.33 (1H, t, J = 7.25 Hz), 7.38-7.46 (4H, m), 7.58-7.63 (4H, m). ESI-MS: 501.2
(M+23). HPLC1: 254 nm tR 7.13 min, purity 41%.
(4-[1-(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-4-(1-hydroxy-ethylidene)3,5-dioxo-pyrrolidin-2-yl]-butyl)-carbamic acid tert-butyl ester (4b). A portion of tbutanol was thawed, and a quantity (5 mL) of it was added to 3b (0.109 g, 0.225 mmol).
To this solution was added potassium t-butoxide (0.070 g, 0.724 mmol), slowly. The
reaction was stirred for 1 h at 40°C, then 8 mL water and 8 mL of 1 N HCl were added.
The reaction was extracted with 3 x 20 mL CH2Cl2, then worked up as in the general
procedure to yield 0.097 g (95.7%) of product as yellow gel. 1H NMR (500 MHz,
CDCl3): δ 0.78 (0.41H, s), 0.83 (3H, s), 1.02 (1H, d, J = 9 Hz), 1.07-1.16 (1.28H, m),
1.22-1.30 (4.94, m), 1.40-1.52 (12.64H, m), 1.68-1.79 (1.14H, m), 1.84-1.94 (1.14H, m),
1.97 (0.94H, t, J = 5 Hz), 2.03 (0.27H, s), 2.06-2.12 (1.24H, m), 2.18-2.22 (0.35H, m),
2.22-2.25 (0.83H, m), 2.27-2.31 (0.79H, m), 2.31-2.37 (1.33H, m), 2.43 (2.64H, s), 2.52
(0.41H, s), 3.00-3.15 (2.31H, m), 3.30 (0.81H, d, J = 14.5 Hz), 3.63-3.68 (0.82H, m),
3.72-3.84 (0.29H, m), 4.11 (0.18H, q, J = 7.5Hz), 4.49-4.64 (2H, m), 5.39-5.48 (0.24H,
m), 5.50 (0.85H, s). ESI-MS: (+) 469.2 (M + 23), (-) 445.1 (M - 1). HPLC2: 254 nm tR
3.20 min, purity 99%.
(4-[1-Decyl-4-(1-hydroxy-ethylidene)-3,5-dioxo-pyrrolidin-2-yl]-butyl)-carbamic
acid tert-butyl ester (4c). A portion of t-butanol was thawed, and a quantitiy (8 mL) of
it was added to 3c (0.442 g, 0.912 mmol). To this solution was added potassium tbutoxide (0.307 g, 2.74 mmol), slowly. The reaction was stirred for 2 h at 35°C, then 20
mL water and 20 mL of 1 N HCl were added. The solution was extracted with 40 mL,
then 3 x 30 mL CH2Cl2, then worked up as in the general procedure to yield 0.405 g
(98.3%) of product as dark brown oil. 1H NMR (500 MHz, CDCl3): δ 0.83 (3H, t, J = 7
Hz), 1.03-1.14 (1.28H, m), 1.14-1.32 (14.1H, closely spaced uneven peaks), 1.34-1.61
(10.75Hz, two single peaks among a multiplet), 1.66-1.75 (0.76H, m), 1.84-1.96 (0.84H,
m), 1.99 (0.17H), 2.17 (0.5H, s), 2.27 (0.17H, t, J = 7.5 Hz), 2.38 (2H, s), 2.47 (0.23H,
bs), 2.83-3.08 (2.05H, m), 3.58-3.65 (0.39H, m), 3.73-3.83 (1.38H, m), 3.86-3.96 (0.41H,
m), 4.70 (0.39H, bs). ESI-MS: 475.3 (M + 23). HPLC2: 254 nm tR 4.38 min, purity
79%.
(4-[1-(4-Ethyl-benzyl)-4-(1-hydroxy-ethylidene)-3,5-dioxo-pyrrolidin-2-yl]-butyl)carbamic acid tert-butyl ester (4d). A portion of t-butanol was thawed, and a quantity
(5 mL) of it was added to 3d (0.186 g, 0.402 mmol). To this solution was added sodium
t-butoxide (0.116 g, 1.206 mmol), slowly. The reaction was stirred for 1.5 h at 40°C,
then 10 mL 1 N HCl was added. The solution was extracted with 3 x 25 mL CH2Cl2,
then worked up as in the general procedure to yield 0.078 g (43.9%) of product as dark
orange oil. 1H NMR (500 MHz): 0.92 (0.37H, q, J = 7 Hz), 1.00-1.11 (1H, m), 1.111.18 (0.81H, m), 1.21 (3H, t, J = 7.5 Hz), 1.24 (0.52H, s), 1.29 (0.5H, s), 1.30-1.41
(1.69H, m), 1.44 (6.37H, s), 1.47 (1.78H, s), 1.50 (0.41H, d, J = 6.5 Hz), 1.69-1.89
(1.89H, m), 2.21 (0.66H, s), 2.44 (2.32H, s), 2.62 (2H, q, J = 7.5 Hz), 2.94 (1.27H, m),
3.33 (0.29H, s), 3.37 (2H, s), 3.59 (0.42H, t, J = 6.25 Hz), 3.97 (0.42H, q, J = 12.5 Hz),
4.26 (0.81H, t, J = 14 Hz), 4.92 (1H, dd, J1 = 15 Hz, J2 = 5.5 Hz), 5.03 (2.92H, bs), 7.18
(2H, d, J = 7.5 Hz), 7.24 (2H, d, J = 7.5 Hz) ESI-MS: (+) 485.3 (M + 23), (-) 451.1 (M –
1). HPLC1: 254 nm tR 7.25 min, purity 84%.
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(4-[4-(1-Hydroxy-ethylidene)-1-(4-methoxy-benzyl)-3,5-dioxo-pyrrolidin-2-yl]butyl)-carbamic acid tert-butyl ester (4e). A portion of t-butanol was thawed, and a
quantity (5 mL) of it was added to 3e (0.112 g, 0.241 mmol). To this solution was added
sodium t-butoxide (0.070 g, 0.724 mmol), slowly. The reaction was stirred for 1 h, then 8
mL water and 1 N HCl were added. The solution was extracted with 3 x 25 mL CH2Cl2,
then worked up as in the general procedure to give the product in quantitative yield
(0.108 g). 1H NMR (500 MHz, CD3OD): δ 0.80-0.87 (0.62H, q, J = 9 Hz), 0.90-1.13
(2.0H, m), 1.16 (1.37H, s), 1.18-1.42 (11.78H; m, but with a singlet at 1.352), 1.62-1.80
(1.94H, m), 2.13 (0.20,H, s), 2.20 (0.22H, s), 2.36 (2.22H, s), 2.82-2.90 (1.67H, m), 3.24
(0.58H, quintet, J = 1.5 Hz), 3.28 (0.92H, s), 3.63 (0.73H, bs), 3.70 (3H, s), 4.11 (0.73H,
d, J = 14.5 Hz), 4.45 (0.30H, s), 6.78-6.84 (2H, m), 7.13-7.21 (2H, m). ESI-MS: (+)
455.3 (M + 23), (-) 431.0 (M - 1). HPLC1: 254 nm tR 6.74 min, purity 92%.
1-(6,6-Dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-5-(4-hydroxy-benzyl)-3-(1hydroxy-ethylidene)-pyrrolidine-2,4-dione (6). A portion of t-butanol was thawed, and
a quantity (12 mL) of it was added to 3f (0.287 g, 0.693 mmol). To this solution was
slowly added sodium t-butoxide (0.233 g, 2.079 mmol). The reaction was stirred for 1 h
at 40°C, then 10 mL water and 10 mL of 1 N NaOH were added. The reaction mixture’s
pH was brought to approximately 4 with concentrated HCl solution and potassium tbutoxide, then extracted with 3 x 60 mL CHCl3, then worked up as in the general
procedure to give the product in quantitative yield. 1H NMR (500 MHz, CD3OD): δ 0.81
(0.77H, s), 0.87 (3H, s), 1.11 (1H, d, J = 8.5 Hz), 1.17 (0.29H, d, J = 8.5 Hz), 1.24
(0.51H, s), 1.26 (1.19H, d, J = 1.5H), 1.27 (0.28H, s), 1.30 (3.16H, s), 1.96 (1H, broad
triplet, J = 5 Hz), 2.03 (0.88H, s), 2.05-2.07 (0.27H, m), 2.07-2.13 (1.34H, m), 2.22-2.25
(0.42H, m), 2.26-2.29 (1.27H, m), 2.30-2.33 (0.86H, m), 2.36 (4.20H, s), 2.37-2.46
(1.28H, m), 2.98 (0.1H, d, J ≈ 4.5 Hz), 3.00 (0.5H, t, J = 4.2 Hz), 3.03 (0.7H, J = 4.5 Hz),
3.08 (0.68H, J = 4.5H), 3.11 (0.50H, J = 4.2), 3.15 (0.12H, d, J ≈ 4.5 Hz), 3.37 (9.28H,
s), 3.51 (0.61H, two close singlets), 3.58 (0.60H, two singlets), 3.92-3.96 (0.91H, bs),
4.05-4.08 (0.23H, bs), 4.12 (0.61H, q, J = 7 Hz), 4.44-4.52 (1.26H, m), 5.32 (0.25H, s),
5.42 (1.01H, s), 6.67 (2.47H, d, J = 8.5 Hz), 6.95 (2.48H, d, J = 8 Hz). ESI-MS: 404.2
(M + 23). HPLC3: 254 nm, tR 5.90 min, Purity 98%.
General procedure for primary amine formation from Boc-protected tetramic acids
(5a-e). To the corresponding tetramic acid (4a-e) was added THF, followed by
approximately 0.5 equivalents TFA. The solution was stirred for 1 h at rt, then
evaporated to dryness.
5-(4-Amino-butyl)-1-biphenyl-4-ylmethyl-3-(1-hydroxy-ethylidene)-pyrrolidine-2,4dione (5a). To 0.114 g (0.238 mmol) of 4a were added 1 mL THF, followed by 1 mL
TFA. The mixture was stirred for 4 h at r. t., then evaporated. The reaction was then
repeated again with 1 mL THF and 1 mL TFA overnight, then evaporated to dryness.
1
H NMR (300 MHz, CDOD3): 0.99-1.33 (2.48H, m), 1.42 (2.33H, s), 1.45-1.64 (1.63H,
m), 1.71-2.00 (1.94H, m), 2.47 (2.32H, s), 2.80 (1.31H, t, J = 6.75 H), 2.88-2.98 (0.37H,
m), 3.32 (0.71H, s), 3.72-3.87 (0.72H, m), 4.26-4.44 (0.81H, m), 4.86-5.16 (5.73H,
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closely spaced singlets), 7.23-7.49 (5.03H, m), 7.50-7.71 (4H, m), 7.84-7.92 (0.42H, m).
ESI-MS: 379.2 (M + 1). HPLC1: 254 nm, tR 5.42 min, purity 86%.
5-(4-Amino-butyl)-1-(6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)-3-(1hydroxy-ethylidene)-pyrrolidine-2,4-dione (5b). To 0.81 g (0.182 mmol) of 4b were
added 1 mL THF and 0.5 mL TFA. The reaction was stirred at r. t. for approximately 1.5
h, then evaporated. The product was then reacted again with 1 mL THF and 0.5 mL TFA
for 1 h, then evaporated to a dark brown gel. 1H NMR (500 MHz): 0.74-0.80 (1H, m),
0.83 (3H, s), 0.97-1.06 (1H, m), 1.06-1.20 (1.93H, m), 1.21-1.31 (5H; mainly a single
large peak), 1.31-1.38 (1.57H, m), 1.46 (3.67H, s), 1.60 (0.68H, s), 1.63-1.81 (4H, m),
1.81-2.02 (6.09H, m), 2.02-2.07 (1.28H, m), 2.17 (1.74H, bs), 2.18-2.32 (2.92H, m),
2.32-2.40 (1.64H, m), 2.41-2.49 (3.43H; two unequal peaks); 2.53 (0.54H, t, J = 8 Hz),
2.95-3.12 (2.12H, m), 3.32 (0.87H, J = 13.2), 3.43 (0.46H, t, J = 15 Hz), 3.64-4.08 (5.41,
m), 4.08-4.18 (0.44H, m), 4.33-4.46 (1.12H, m), 4.47-4.57 (0.92H, m), 5.41 (0.35H, s),
5.49 (0.9H, s), 7.48 (1.88H, s). ESI-MS: (+) 347.2 (M + 1). HPLC2: 254 nm, tR 1.68
min, purity 88%.
5-(4-Amino-butyl)-1-decyl-3-(1-hydroxy-ethylidene)-pyrrolidine-2,4-dione (5c). To
0.392 g (0.866 mmol) of 4c were added 3 mL THF and 2 mL TFA. The reaction was
stirred at r. t. for 1 h, then evaporated. The solution was then reacted again with 3 mL
THF and 2 mL TFA, then evaporated to a somewhat darker brownish oil. Prior to
antimicrobial testing, portions of this product were purified by use of a Gilson preparative
HPLC reversed-phase column and combined. 1H NMR (500MHz, CDCl3): 0.92 (3H, t),
1.08-1.18 (0.88H, m), 1.18-1.37 (15.41H, m dominated by large singlet), 1.39-1.53
(5.75H, m including large singlet), 1.54-1.64 (1.56H, m), 1.66-1.81 (1.71H, m), 1.87-2.02
(1.75H, m), 2.06 (0.81H, s), 2.19 (0.19H, s), 2.24-2.29 (0.36H, m), 2.29-2.34 (0.34H, m),
2.34-2.36 (0.19H, m), 2.4 (2.32H, dd, J = 10 Hz), 2.98-3.12 (2.09H, m), 3.18-3.28
(0.36H, m), 3.72-3.90 (2.34H, m), 4.12 (0.4H, q, J = 7.17 Hz), 4.23-4.42 (0.43H, m), 7.61
(0.7H, bs). ESI-MS: 475.3 (M+23). HPLC3: 254 nm, tR 4.52 min, purity 59%.
5-(4-Amino-butyl)-1-(4-ethyl-benzyl)-3-(1-hydroxy-ethylidene)-pyrrolidine-2,4dione (5d). To 0.078 g of 4d were added 1 mL THF and 0.5 mL TFA. The reaction was
allowed to proceed at r. t. for 11.5 h, then evaporated to form a brown sticky semisolid.
1
H NMR (500 MHz, CD3OD): 0.88-0.94 (0.87H, m), 1.01-1.09 (0.60Hz, m), 1.10-1.18
(0.79H, m), 1.23 (3.60H, t, J = 7.5 Hz), 1.26-1.39 (4.14H, m), 1.44 (4H, s), 1.72-1.95
(1.93H, m), 2.47 (2H, s), 2.65 (2H, q, J = 7.67 Hz), 2.78-2.84 (0.42H, m), 2.94 (0.67H, t,
J = 6.25), 3.33 (2.32H, t, J = 1.5 Hz), 3.72-3.80 (0.66H, m), 4.25-4.31 (0.53H, d, J = 15
Hz), 4.85-4.98 (17H, large singlet and small multiplet), 7.13-7.28 (3.43H, m). ESI-MS:
(+) 331.2 (M + 1). HPLC1: 254 nm, tR 5.27 min, purity 41%.
5-(4-Amino-butyl)-3-(1-hydroxy-ethylidene)-1-(4-methoxy-benzyl)-pyrrolidine-2,4dione (5e). To 0.56 g (0.13 mmol) of 4e were added 2 mL THF and 0.5 mL TFA. The
reaction was stirred for 1.5 hours at r. t., then evaporated. The product was then reacted a
second time with 1 mL THF and 0.5 mL TFA for 1 h, then evaporated to form a brown
sticky semisolid. 1H NMR (500 MHz, CD3OD): 0.92 (0.94H, t, J = 6.75 H), 1.08-1.26
(2.42H, m), 1.26-1.38 (8.28H, m), 1.39-1.46 (3.09H, m, two main peaks), 1.48-1.63
(1.87H, m), 1.73-1.94 (1.88H, m), 2.22 (0.36H, t, J = 8 Hz), 2.29 (0.38H, t, J = 7.5 Hz),
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2.46 (2.38H, s), 2.61 (0.17H, s), 2.82 (1.2H, t, J = 6.75 Hz), 2.92-2.98 (0.46H, m), 3.23
(2H, q, J = 7.67 Hz), 3.33 (1.24H, s), 3.37 (1.62H, s), 3.70-3.83 (4.18H, single peak amid
multiplet), 4.19-4.30 (0.86H, mainly doublet at 4.26 and J = 15 Hz), 4.85-5.03 (8.7H,
singlet merged with smaller peaks), 6.91 (2H, d, J = 7 Hz), 7.27 (2H, d, J = 7.5 Hz). ESIMS: (+) 333.2 (M + 1). HPLC4: 254 nm, tR 6.34 min, purity 81%.
Biology
Microbiological Testing
The minimum inhibitory concentrations (MICs) of the tetramic acids were determined by
incubation in Mueller-Hinton media in 96-well microplates containing doubling dilutions
of antibiotic, with bacterial concentration of approximately 105 colony-forming units per
milliliter. After overnight growth at 37°C, the MIC was recorded as the lowest
concentration of antibiotic that impeded visible bacterial growth.
Hemolysis Assay
The hemolytic activity of tetramic acids against mammalian blood cells was tested
against horse erythrocytes (BD Biosciences). A stock suspension (10% vol/vol) was
prepared in phosphate-buffered saline (pH 7.2). Before analysis, the stock suspension
was diluted to 1 in 20 with saline, and 360 µL aliquots were measured into sterile
microcentrifuge tubes. Following incubation for 15 min at 37°C, 40 µL of tetramic acid
compounds were added to give final concentrations of 100, 10, or 1 µg/mL. The
antibiotics used as non-hemolytic negative controls, ampicillin and doxycycline, were
tested at a concentration of 10 µg/mL, whereas the positive control, the detergent TritonX 100 (inducing 100% lysis), was tested at 0.1% vol/vol. After an incubation period of 1
h at 37°C, the reaction mixtures were centrifuged and 200 µL of supernatant transferred
to 96 well flat-bottom microtiter plates. The absorbance of hemoglobin released from
cells was determined by OD540nm readings on a Synergy HT Biotek plate reader. Based
on OD540nm readings, the % hemolysis was determined as 100 x (OD540 of sample - OD540 of
sample blank) / (OD540 of Triton-X 100 - OD540 of Triton-X blank).
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